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Genetic variationThe requirement to replicate in both vertebrate and invertebrate hosts is thought to limit the introduction of
genetic changes into the genome of arboviruses. Serial passage under laboratory conditions will overcome this
limitation allowing for genetic changes to be introduced and affecting the virulence of the virus for animals. In
the studies detailed here, the consequence of removing the restriction of alternate replication was
demonstrated to be different depending on the virus. Passing Venezuelan equine encephalitis virus in tissue
culture cells, eggs or mice resulted in up to 11 nucleotide or amino acid changes but no signiﬁcant change in
the virulence of the virus for mice. Passing Japanese encephalitis virus (JEV) under the identical conditions
resulted in as many as 22 nucleotide or amino acid changes that often resulted in improved survival
probabilities. For JEV, most genetic changes along with the attenuated phenotype were selected within 5
passes..
l rights reserved.© 2011 Elsevier Inc. All rights reserved.Introduction
Venezuelan equine encephalitis virus (VEEV, genus Alphavirus,
family Togaviridae) and Japanese encephalitis virus (JEV, genus
Flavivirus, family Flaviviridae) share common characteristics including
a positive-sense, single-stranded RNA genome; an enveloped icosa-
hedral nucleocapsid; and transmission between susceptible verte-
brate hosts by arthropod vectors (Geiss et al., 2009; Gould et al., 2009;
Jose et al., 2009). In general, RNA viruses have the capacity for
signiﬁcant genetic variation due to the error prone nature of the viral
RNA-dependent RNA polymerase which is responsible for replication
of the viral genome but has no proofreading activities (Drake and
Holland, 1999; Duarte et al., 1994; Steinhauer et al., 1992).
Paradoxically, the genomic sequence of arthropod-borne RNA viruses,
such as those in the alphavirus and ﬂavivirus genera, remain stable
over long periods of time when compared to viruses transmitted
directly between susceptible hosts, likely due to the requirement for
alternate replication in vertebrate and invertebrate hosts (Jenkins
et al., 2002; Vasilakis et al., 2009).Although humans do not participate in the transmission cycle of
VEEV and JEV, humans are susceptible to infection, often with
signiﬁcant morbidity and mortality (Calisher, 1994; Erlanger et al.,
2009; Mackenzie et al., 2004; Zacks and Paessler, 2010). Most people
infected with enzootic strains of VEEV (subtypes IAB and IC) will
develop an acute, febrile disease, which may be incapacitating and
have a prolonged convalescence period. Approximately 14% of cases
will progress to neurological involvement and encephalitis with a 1%
fatality rate (Franz et al., 2001; Zacks and Paessler, 2010). VEEV is also
highly infectious by the aerosol route and has been associated with
numerous laboratory acquired infections (Bellamy and Freedman,
2001; Kadlec et al., 1997; Zacks and Paessler, 2010). JEV is the leading
cause of viral encephalitis in Asia and nearly half of the current human
population lives in JEV endemic areas (Erlanger et al., 2009; Lowry
et al., 1998). The annual incidence of Japanese encephalitis ranges
from 30,000 to 50,000 cases, with mortality estimated to be between
25% and 30%. A third of survivors are left with signiﬁcant neurologic
sequelae including memory loss, motor weakness and behavioral
disturbances. VEEV and JEV are both listed as priority pathogens by
the National Institute of Allergy and Infectious Diseases because of
their potential to be used as biological weapons.
The theory of constrained evolution as a result of alternating hosts is
supported by numerous studies in which alphaviruses or ﬂaviviruses
Table 1
Nucleotide and amino acid changes in VEEV following passage.
Regiona Positionb Virus stock
VEEV
TRD
VEEV
Vero
VEEV
C6/36
VEEV
Alt
VEEV
Egg
VEEV
MB
5′ NCR – – – – – – –
nsP1 – – – – – – –
nsP2 aa466 Pro – Pro/Leu – – –
nsP3 aa288 Gln – – Arg – –
aa471 His His/Arg – – – –
aa478 Thr – Thr/Ile – – –
nsP4 aa207 Val – Val/Ile – – –
aa451 Glu – Glu/Lys – – –
C aa54 Asp – Asp/Asn – – –
E3 – – – – – – –
E2 aa56 Asp – – – Gly –
aa120 Lys/Thrc Lys Lys Lys Thr Thr
aa158 Ala – – – Glu –
aa159 Gln Gln/Pro – – – –
aa165 Val – Val/Ala – – –
aa168 His – His/Arg – – –
aa205 Thr Lys Thr/Lys – – Lys
aa211 Asn – Asn/Tyr – – –
6K protein aa51 Ala – Ala/Thr – – –
E1 aa248 Pro – – Thr – –
3′ NCR nt11393 U – – – A –
–, no change.
a Non-coding region (NCR) or viral protein.
b Nucleotide (nt) or amino acid (aa) position within the viral genome or within a
given gene.
c Mixed population.
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brate hosts (Ciota et al., 2009; Coffey et al., 2008; Greene et al., 2005;
Jerzak et al., 2007; Jerzak et al., 2008; Vasilakis et al., 2009;Weaver et al.,
1999). Generally speaking, passing a virus sequentially in a speciﬁc host
type resulted in the introduction of genetic changes and corresponding
ﬁtness gains for that host, whilst diminishing ﬁtness in the alternate
host. Alternately passing an alphavirus or a ﬂavivirus between
vertebrate and invertebrate hosts, as occurs in nature, resulted in
fewer genetic substitutions and either no change in the ﬁtness of the
virus or increased ﬁtness for both hosts. The number and rate at which
genetic changes accumulate in or between alphaviruses or ﬂaviviruses
following sequential passage in vitro and in vivowere not compared in
these studies. Additionally, the effect of serial passage on the phenotype
of the virus in an animal model was often not assessed.
Live attenuated vaccines for many different viruses, including VEEV
and JEV, have been developed by repeated in vitro passage (Ada, 2001;
Kinney et al., 1993;Ni et al., 1995;Nitayaphan et al., 1990). Themethods
used to perform these passages were different for VEEV and JEV;
however, it is notable that there were a minimum of 45 nucleotide
changes and 15 amino acid changes introduced into the JEV genome
following passage to select for an attenuated virus (Nitayaphan et al.,
1990) as compared to 12 nucleotide and 8 amino acid changes
introduced following passage of VEEV (Kinney et al., 1993). The effect
of alternating passage of VEEV and JEV between vertebrate and
invertebrate cells on the virulence of the virus has not been assessed,
however if this method serves to constrain the introduction of genetic
changes in the virus, then it would be reasonable to assume that passing
the virus in this way would also conserve the virulence of the virus.
Repeated passage of some viruses in vivo has also been used to
develop live attenuated vaccines in the past (Ada, 2001); however, for
Sindbis virus (SINV), an alphavirus, and St. Louis encephalitis virus
(SLEV), a ﬂavivirus, repeated passage in animals selected for genetic
variants with increased infectivity for that animal (Ciota et al., 2009;
Lustig et al., 1992). For SINV, passage inmouse brains resulted in a virus
that demonstrated increased neurovirulence and neuroinfectivity in
mice when compared to the original virus. Similarly, passing SLEV in
chickens resulted in a virus with increased infectivity for chickens;
however, the pathogenicity of SLEV in comparison to the parentwas not
assessed and increased infectivity was not observed in all chicken
passage lineages. These conﬂicting results suggest that the effect of
passing viruses in animals is uncertain andmay dependon the virus and
the passage conditions.
Tissue culture cells, sucklingmice and eggs each represent vehicles
that can be used to propagate VEEV and JEV. Based on the results of
previous studies summarized above, it would be predicted that
passage of these viruses in or between mammalian and mosquito
tissue culture cells would result in the accumulation of genetic
changes and viral attenuation. The effect of passing VEEV and JEV in
eggs or mice is less certain but would be expected to at least retain the
virulence properties of the viruses. In order to test these predictions
VEEV and JEV were passed up to 40 times in or between vertebrate
and invertebrate tissue culture cells, and in suckling mice and eggs a
total of 20 times. The genomic sequence of the resulting viruses and
their virulence in weanling CD-1 mice were compared.
Results
Accumulation of genetic changes following passage of VEEV
The genetic changes observed following passage of VEEV in Vero
(African greenmonkey kidney) cells; C6/36 (Aedes albopictusmosquito)
cells; alternately between Vero and C6/36 cells (Alt); in suckling mice
(MB); or in eggs are summarized in Table 1. The VEEV Trinidad Donkey
(VEEV TRD) strain was used to initiate each of the passage stocks and
serves as the reference strain for all VEEV comparisons. VEEV TRD is
commonly used in laboratory experiments to represent fully virulentVEEV; however the passage history prior to initiating these studies is
unknown and the implications on the results are discussed.
Sequencing of the VEEV TRD stocks indicated a mixed population
of Lys or Thr at amino acid 120 of the E2 glycoprotein (E2 120). Mixed
populations were identiﬁed as multiple peaks within the chromato-
gram at a given nucleotide position. Because consensus sequencing
was used for these experiments single peaks indicate that a given
nucleotide was present in the majority population. Passing VEEV TRD
in, or alternating between Vero and C6/36 cells, up to 40 times
selected for Lys at this position; while passing in eggs or sucklingmice
up to 20 times selected for Thr. VEEV Egg had two additional amino
acid changes in the E2 glycoprotein plus a nucleotide change in the 3′
non-coding region (NCR) that were not introduced until after 15
passes (data not shown). VEEVMB had only one additional amino acid
change in the E2 glycoprotein.
It took between 15 and 20 passes for Lys to become predominant in
the majority population at E2 120 of both VEEV Vero and VEEV Alt
(Table 2). Two additional amino acid changes, one in nonstructural
protein 3 (nsP3) and one in the E1 glycoprotein were introduced into
VEEV Alt, between passes 10 and 15, and became predominant in the
majority population between pass 20 and 25. Three additional changes
were present in VEEV Vero after 40 passes includingmixed populations
at E2159andnsP3471 (Table1). Thesegenetic changeswere introduced
after 10 or 15 passes, respectively (Table 2). The amino acid change at E2
205 of VEEV Vero was introduced sometime after the 5th pass and
became predominant in the majority population sometime between 20
and 25 passes. VEEV C6/36 contained a mixed population with 10
variable sites located in the nsP2, nsP3, nsP4, Capsid (C), E2 and 6K
proteins after 40 passes (Table 1). It took more than 30 passes for these
variable sites to be introduced, yet the genetic change at E2 120 became
predominant in the majority population after 10 passes (Table 2).
Effect of passage on the virulence of VEEV
The percent mortality for VEEV stocks is calculated as the total
number of mice that died as a result of virus challenge versus the total
number of mice challenged and is presented in Fig. 1. VEEV TRD
Table 2
Accumulation of amino acid changes in VEEV following passage in tissue culture cells.
Regiona Positionb Virus stock
VEEV TRD VEEV Vero P5 VEEV Vero P10 VEEV Vero P15 VEEV Vero P20 VEEV Vero P25 VEEV Vero P30 VEEV Vero P35 VEEV Vero P40
nsP1 – – – – – – – – – –
nsP2 – – – – – – – – – –
nsP3 aa471 His – – – His/Arg His/Arg His/Arg His/Arg His/Arg
nsP4 – – – – – – – – – –
C – – – – – – – – – –
E3 – – – – – – – – – –
E2 aa120 Lys/Thr Lys Lys/Thr Lys/Thr Lys Lys Lys Lys Lys
aa159 Gln – – Gln/Pro Gln/Pro Gln/Pro Gln/Pro Gln/Pro Gln/Pro
aa205 Thr – Thr/Lys Thr/Lys Thr/Lys Lys Lys Lys Lys
6K – – – – – – – – – –
E1 – – – – – – – – – –
Region Position Virus stock
VEEV TRD VEEV C6/36 P5 VEEV C6/36 P10 VEEV C6/36 P15 VEEV C6/36 P20 VEEV C6/36 P25 VEEV C6/36 P30 VEEV C6/36 P35 VEEV C6/36 P40
nsP1 – – – – – – – – – –
nsP2 aa466 Pro – – – – – – Pro/Leu Pro/Leu
nsP3 aa478 Thr – – – – – – Thr/Ile Thr/Ile
nsP4 aa207 Val – – – – – – Val/Ile Val/Ile
aa451 Glu – – – – – – Glu/Lys Glu/Lys
C aa54 Asp – – – – – – Asp/Asn Asp/Asn
E3 – – – – – – – – – –
E2 aa120 Lys/Thr Lys Lys/Thr Lys Lys Lys Lys Lys Lys
aa165 Val – – – – – – Val/Ala Val/Ala
aa168 His – – – – – – – His/Arg
aa205 Thr Thr/Lys Thr Thr Thr Lys Lys Lys Thr/Lys
aa211 Asn – – – – – – – Asn/Tyr
6K aa51 Ala – – – – – – Ala/Thr Ala/Thr
E1 – – – – – – – – – –
Regiona Positionb Virus stock
VEEV TRD VEEV Alt P5 VEEV Alt P10 VEEV Alt P15 VEEV Alt P20 VEEV Alt P25 VEEV Alt P30 VEEV Alt P35 VEEV Alt P40
nsP1 – – – – – – – – – –
nsP2 – – – – – – – – – –
nsP3 aa288 Gln – – Gln/Arg Gln/Arg Arg Arg Arg Arg
nsP4 – – – – – – – – – –
C – – – – – – – – – –
E3 – – – – – – – – – –
E2 aa120 Lys/Thrc – – – Lys Lys Lys Lys Lys
6K – – – – – – – – – –
E1 aa248 Pro – – Pro/Thr Pro/Thr Thr Thr Thr Thr
–, no change.
a Viral protein.
b Amino acid (aa) position within a given gene.
c Mixed population.
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(SC) route and 60% mortality via the intranasal (IN) route. Whenmice
were challenged with VEEV Vero, VEEV C6/36, VEEV Alt, VEEVMB and
VEEV Egg via the IN route, no signiﬁcant differences were observed in
the percent mortality when compared to VEEV TRD (Fig. 1). With the
exception of VEEV Vero (P=0.022) survival probabilities, following
IN exposure were also not signiﬁcantly affected (Fig. 2). Survival
probabilities focus on the time to death as well as the probability of
death; thus for VEEV Vero the survival curve was statistically different
when compared to VEEV TRD even though the percent mortality did
not change signiﬁcantly. Following SC exposure, the percent mortality
was decreased when mice were challenged with VEEV C6/36 only
(P=0.033); however survival probabilities improved when mice
were challenged with VEEV Vero (P=0.001), VEEV Alt (Pb0.001) and
VEEV Egg (P=0.028) in addition to VEEV C6/36 (P=0.003). The
survival probability for mice challenged with VEEV MB decreased
(P=0.001) in comparison to VEEV TRD following SC exposure though
the percent mortality was unchanged. Virulence studies conducted
using earlier passes of VEEV with unique genetic changes did not
provide any signiﬁcant data that would help to determine the role of
speciﬁc genetic changes on the virus phenotype (data not shown).Accumulation of genetic changes following passage of JEV
Based onwhole genome sequencing, the stock of JEVNakayama (JEV
Nak)whichwas used to initiate passage studies for JEV containedmixed
populations of Lys or Arg at amino acid 209 of the Envelope (E) protein
andamino acid 8ofnon-structural protein4b (NS4b); Ile orVal at amino
acid 405 of the NS5 protein; cytidine (C) or uracil (U) at nucleotide
10431 of the 3′ NCR; and adenosine (A) or Guanosine (G) at nucleotide
10434 of the 3′NCR (Table 3). As with VEEV TRD, the passage history of
JEV Nakayama prior to initiating these studies was not known. Passing
JEV Nak in or between mammalian and mosquito cells selected for Lys
at E 209 and NS4b 8 and A at nucleotide 10431 of the 3′NCR. Passage in
eggs or mice selected for Arg or G at these positions, respectively. Val
was selected atNS5405 andUwas selected at nucleotide10431 of the 3′
NCR regardless of the passage condition.
JEVMBand JEVEgghave oneand twoadditional aminoacid changes,
respectively, in comparison to JEV Nak that were conﬁned to the E
protein (Table 3). None of these changes was conserved between JEV
MB and JEV Egg. Genetic changes observed in JEV Egg were introduced
after 5 or more passes and became predominant in the majority
population sometime before 20 passes (data not shown).
Fig. 1. Percent mortality and 95% conﬁdence bounds for weanling CD-1 mice challenged by the IN or SC routes with 1×104 pfu VEEV TRD (parent), VEEV Vero, VEEV C6/36, VEEV Alt,
VEEV Egg or VEEV MB.
23K. McCurdy et al. / Virology 415 (2011) 20–29Passing JEV Nak in tissue culture cells resulted in numerous
additional genetic changes that were distributed throughout the viral
genome (Table 3). JEV Alt had 21 nucleotide or amino acid changes in
comparison to JEV Nak. JEV Vero had 22 changes in total and JEV C6/36
had 21. Of these nucleotide and amino acid changes, 17were conserved
between JEV Alt, JEV Vero and JEV C6/36. Conserved genetic changes
were observed in the 5′ and 3′NCR, and in the capsid (C), E, NS1, 2K, andFig. 2. Kaplan–Meier survival curves for weanling CD-1 mice challenged with 1×104 pfu V
administration. (B)=SC administration.NS4b proteins (Table 3). Each of these conserved changes was selected
within the ﬁrst 5 passes of JEV Alt, JEV Vero and JEV C6/36 (Table 4).
Effect of passage on the virulence of JEV
IN and SC exposure of weanling CD-1micewith JEVNak resulted in
80% and 90% mortality, respectively (Fig. 3). Challenging mice withEEV TRD (parent), VEEV Vero, VEEV C6/36, VEEV Alt, VEEV Egg or VEEV MB. (A)=IN
Table 3
Nucleotide and amino acid changes in JEV following passage.
Regiona Positionb Virus Stock
JEV Nak JEV Vero JEV C6/36 JEV Alt JEV Egg JEV MB
5′ NCR nt14 C U U U – –
nt49 U C C C – –
C aa120 Ile Val Val Val – –
PreM aa110 Ala Val – – – –
E aa82 Lys – Glu – – –
aa83 Lys Glu Lys/Glu Glu – –
aa124 Lys – – Lys/Glu – –
aa176 Thr Ile Ile Ile – –
aa191 Glu – – Ala – –
aa209 Lys/Argc Lys Lys Lys Arg Arg
aa228 Pro – – – Ala –
aa232 Ala – – – Val –
aa275 Asn – – – – Asp
aa290 Arg Lys Lys Lys – –
aa306 Glu – Glu/Gly – – –
aa418 Val Ala Ala Ala – –
NS1 aa8 Val Ile Ile Ile – –
NS2a – – – – – – –
NS2b – – – – – – –
NS3 aa249 Gln – Gln/Arg – – –
aa443 Ile Leu – – – –
aa518 Leu Phe – Phe – –
NS4a – – – – – – –
2K aa20 Met Val Val Val – –
NS4b aa8 Lys/Arg Lys Lys Lys Arg Arg
aa110 Val Phe Phe Phe – –
NS5 aa405 Ile/Val Val Val Val Val Val
aa643 Arg Lys – – – –
3′ NCR nt10408 A – – – A/G –
nt10410 G A A A – –
nt10431 C/U U U U U U
nt10434 A/G A A A G G
nt10448 G A A A – –
nt10554 G A A A – –
–, no change.
a Non-coding region (NCR) or viral protein.
b Nucleotide (nt) or amino acid (aa) position within the viral genome or within a
given gene.
c Mixed population.
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percent mortality in comparison to JEV Nak and the survival
probabilities were unchanged (Fig. 4). A signiﬁcant decrease in the
percent mortality and improved survival probabilities were observed
in mice challenged IN with JEV Vero, JEV C6/36 and JEV Egg (P=0.005
or less). Following SC exposure JEV Vero, JEV Alt, JEV Egg, and JEV MB
all demonstrated a decrease in percent mortality when compared to
JEV Nak; however only VEEV C6/36 demonstrated a signiﬁcant
decrease (P=0.001). All passage stocks exhibited signiﬁcantly
improved survival probabilities when compared with JEV Nak
following SC exposure (P=0.019 or less). The decrease in percent
mortality following SC exposure of mice with JEV Vero, JEV C6/36, JEV
Alt and JEV Egg, was conﬁrmed in pass 5 stocks (data not shown).
Because all of the conserved genetic changes observed in JEV were
present in the pass 5 stocks the contribution of speciﬁc genetic
changes on the attenuated phenotype could not be determined.
Discussion
These studies demonstrate conclusively that the consequence of
eliminating alternate replication in vertebrate and invertebrate cells
on the accumulation of genetic changes in VEEV and JEV is different
and may be dependent on the method in which the virus is cultured.
For VEEV, few genetic changes were observed during the course of
these investigations, and as a result, the percent mortality in mice was
not signiﬁcantly altered. A Lys residue at E2 120 is a known tissue
culture adaptation of VEEV and was previously identiﬁed as being oneof two genetic changes responsible for the attenuation of the VEEV
live vaccine strain TC-83(Kinney et al., 1993). Although the passage
history of VEEV TRD prior to initiating these studies was unknown, the
presence of both Thr and Lys at this position in the stock of VEEV TRD
suggests that the virus had already been partially adapted to growth
in tissue culture cells. Passing VEEV TRD in mouse brains and in eggs
20 times selected for the wild-type Thr at this position. The decreased
survival probability observed with VEEV MB following SC exposure is
consistent with what was observed previously with SINV (Lustig et al.,
1992); but may simply represent a reversion of the virus to the wild-
type phenotype as a result of the E2 120 amino acid change. An
additional amino acid change in the E2 glycoprotein of VEEV MB was
present and a similar phenotype change was not observed with VEEV
Egg; thus additional studies are required to determine the contribu-
tion of these genetic changes to the phenotype of the virus. Passage of
VEEV TRD on or between mammalian and mosquito tissue culture
cells selected for Lys at E2 120 consistent with previous results on
tissue culture adaptation of VEEV TRD (Kinney et al., 1993).
Regardless of whether the virus was passed in vitro or in vivo, 10 to
20 passes of VEEV TRD were required for the amino acid change at E2
120 to become ﬁxed in the population and additional genetic changes
in the VEEV genome were equally slow to develop. Thus, the effect of
different culture methods on the accumulation of genetic changes in
VEEV TRD as observed in these studies is independent of the previous
passage history.
Passing JEV Nak under the identical conditions resulted in
numerous genetic changes that were distributed throughout the
viral genome and in most cases; these genetic changes were
introduced in 5 passes or less and remained ﬁxed in the population
for all subsequent passes. Consequently, all of the viruses generated
following passage of JEV, including those passed in eggs and mice,
demonstrated decreased mortality and improved survival probabili-
ties in mice to different extents depending upon the route of
inoculation. For each of the JEV stocks tested, attenuated virulence
was observed within the ﬁrst 5 passes (data not shown). Because of
the number of genetic changes observed and the rapidity at which
theywere selected for JEV, the contribution of speciﬁc genetic changes
on the virulence of the virus for mice could not be determined by
challenging mice with earlier passes of the virus. Additionally, it has
been demonstrated previously that genetic changes in the NCR and
the nonstructural proteins of ﬂaviviruses as well as the structural
proteins can inﬂuence virus virulence; thus it is not possible to
speculate on the role of individual genetic changes on the observed
phenotype (Butrapet et al., 2000; Chambers et al., 2007; Durbin et al.,
2001). Passing JEV in eggs and mice resulted in the fewest number of
genetic changes although only two were conserved between the in
vitro and in vivo passage stocks. These included a Val residue at NS5
405 and a U at nucleotide 10431 of the 3′ NCR. Passing JEV in or
between Vero and C6/36 cells resulted in 11 nucleotide or amino acid
changes that were conserved and likely represent tissue culture
adaptations. In order to determine the contribution of each of these
amino acid changes on the virus phenotype, each of the nucleotide
and amino acid changes observed in this study could be investigated
individually or in combination using currently available infectious
clones developed in other labs.
The reasons for the differences observed between VEEV and JEV in
these studies was not evaluated and since only one strain of each was
used, it is not possible to know if these observations would apply
equally to other strains of VEEV and JEV or other viruses in the
alphavirus and ﬂavivirus genera. Despite their many similarities, the
organization of the VEEV and JEV genome is dissimilar as is the
manner in which the viral RNA is translated and transcribed [for
reviews see (Fernandez-Garcia et al., 2009; Jose et al., 2009)]. The
genome of JEV encodes a single long polyprotein that is translated to
produce structural and nonstructural proteins simultaneously. The
structural proteins of JEV are produced ﬁrst because of their location
Table 4
Accumulation of amino acid changes in JEV following passage in tissue culture cells.
Regiona Positionb Virus stock
JEV Nak JEV Vero P5 JEV Vero P10 JEV Vero P15 JEV Vero P20 JEV Vero P25 JEV Vero P30 JEV Vero P35 JEV Vero P40
C aa120 Ile Val Val Val Val Val Val Val Val
PreM aa110 Ala – – – – – Ala/Val Ala/Val Val
E aa83 Lys Glu Glu Glu Glu Glu Glu Glu Glu
aa176 Thr Ile Ile Ile Ile Ile Ile Ile Ile
aa209 Lys/Arg Lys Lys Lys Lys Lys Lys Lys Lys
aa290 Arg Lys Lys Lys Lys Lys Lys Lys Lys
aa418 Val Ala Ala Ala Ala Ala Ala Ala Ala
NS1 aa8 Val Ile Ile Ile Ile Ile Ile Ile Ile
NS2a – – – – – – – – – –
NS2b – – – – – – – – – –
NS3 aa443 Ile – – – Leu Leu Leu Leu Leu
aa518 Leu Phe Phe Phe Phe Phe Phe Phe Phe
NS4a – – – – – – – – – –
2K aa209 Met Val Val Val Val Val Val Val Val
NS4b aa8 Lys/Arg Lys Lys Lys Lys Lys Lys Lys Lys
aa110 Val Phe Phe Phe Phe Phe Phe Phe Phe
NS5 aa405 Ile/Val Val Val Val Val Val Val Val Val
aa643 Arg – – – – – – – Lys
Regiona Positionb Virus Stock
JEV Nak JEV C6/36 P5 JEV C6/36 P10 JEV C6/36 P15 JEV C6/36 P20 JEV C6/36 P25 JEV C6/36 P30 JEV C6/36 P35 JEV C6/36 P40
C aa120 Ile Val Val Val Val Val Val Val Val
PreM – – – – – – – – – –
E aa82 Lys Glu Glu Glu Glu Glu Glu Glu Glu
aa83 Lys – – – – – Lys/Glu Lys/Glu Lys/Glu
aa176 Thr Ile Ile Ile Ile Ile Ile Ile Ile
aa209 Lys/Argc Lys Lys Lys Lys Lys Lys Lys Lys
aa290 Arg Lys Lys Lys Lys Lys Lys Lys Lys
aa306 Glu – – – – – Glu/Gly Glu/Gly Glu/Gly
aa418 Val Ala Ala Ala Ala Ala Ala Ala Ala
NS1 aa8 Val Ile Ile Ile Ile Ile Ile Ile Ile
NS2a – – – – – – – – – –
NS2b – – – – – – – – – –
NS3 aa249 Gln – – – – – Gln/Arg Gln/Arg Gln/Arg
aa518 Leu Phe Phe Phe Phe Phe Phe Phe Phe
NS4a – – – – – – – – – –
2K aa209 Met Val Val Val Val Val Val Val Val
NS4b aa8 Lys/Arg Lys Lys Lys Lys Lys Lys Lys Lys
NS5 aa405 Ile/Val Val Val Val Val Val Val Val Val
Regiona Positionb Virus stock
JEV Nak JEV Alt P5 JEV Alt P10 JEV Alt P15 JEV Alt P20 JEV Alt P25 JEV Alt P30 JEV AltP35 JEV Alt P40
C aa120 Ile Val Val Val Val Val Val Val Val
PreM – – – – – – – – – –
E aa83 Lys Glu Glu Glu Glu Glu Glu Glu Glu
aa124 Lys – – – – – – – Lys/Glu
aa176 Thr Ile Ile Ile Ile Ile Ile Ile Ile
aa191 Glu – – – – – – – Ala
aa209 Lys/Arg† Lys Lys Lys Lys Lys Lys Lys Lys
aa290 Arg Lys Lys Lys Lys Lys Lys Lys Lys
aa418 Val Ala Ala Ala Ala Ala Ala Ala Ala
NS1 aa8 Val Ile Ile Ile Ile Ile Ile Ile Ile
NS2a – – – – – – – – – –
NS2b – – – – – – – – – –
NS3 aa518 Leu Phe Phe Phe Phe Phe Phe Phe Phe
NS4a – – – – – – – – – –
2K aa20 Met Val Val Val Val Val Val Val Val
NS4b aa8 Lys/Arg Lys Lys Lys Lys Lys Lys Lys Lys
aa110 Val Phe Phe Phe Phe Phe Phe Phe Phe
NS5 aa405 Ile/Val Val Val Val Val Val Val Val Val
–, no change.
a Viral protein.
b Amino acid (aa) position within a given gene.
c Mixed population.
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to replicate the viral RNA in a continuous cycle. For VEEV, the
nonstructural protein genes are located in the 5′ two-thirds of the
genome and are the ﬁrst to be translated. The nonstructural proteins
of VEEV serve to replicate the viral RNA as well as to produce a
subgenomic RNA that encodes the structural proteins, which areconsequently produced at later points during infection of a cell.
Differences in protein expression and RNA replication affect the way
in which VEEV and JEV viral titers accumulate in infected cells and
animals (data not shown). These differences also may affect the
accumulation of genetic changes in VEEV and JEV accounting for the
disparity observed in these studies. Repeating the passage studies
Fig. 3. Percent mortality and 95% conﬁdence bounds for weanling CD-1 mice challenged by the IN or SC routes with 1×104 pfu JEV TRD (parent), JEV Vero, JEV C6/36, JEV Alt, JEV Egg
or JEV MB.
26 K. McCurdy et al. / Virology 415 (2011) 20–29with different strains of VEEV and JEV as well as different viruses in
the alphavirus and ﬂavivirus genera are required in order to address
this hypothesis.
For VEEV, the synthesis of complementary minus-strand RNAs is
believed to be down regulated during cellular infection to favor the
generation of new genomic and subgenomic RNAs (Jose et al., 2009;Fig. 4. Kaplan–Meier survival curves for weanling CD-1 mice challenged with 1×104 pfu JEV
(B)=SC administration.Shirako and Strauss, 1990). Since minus-strand RNA serves as
template for genomic RNA that is subsequently packaged into
numerous viral particles, genetic changes introduced at this level
would be expected to be present in a greater percentage of the viral
population; whereas genetic changes introduced into the genomic
RNA would only be propagated during subsequent rounds ofTRD (parent), JEV Vero, JEV C6/36, JEV Alt, JEV Egg or JEV MB. (A)=IN administration.
27K. McCurdy et al. / Virology 415 (2011) 20–29infection. Consequently, down regulation of minus-strand RNA
synthesis would be expected to reduce the probability of genetic
changes being introduced into the majority population and might
contribute to the genetic stability observed with VEEV in these
studies. We can test the effects of down regulating minus-strand
synthesis on the stability of the VEEV genome by artiﬁcially
introducing genetic changes into an infectious clone of VEEV that
would allow negative strand RNA synthesis to continue throughout
cellular infection, as was demonstrated for SINV (Gorchakov et al.,
2008), and repeat the passage experiments. If down regulation of
minus-strand RNA synthesis does play a role in stability of VEEV, it
would also be expected that the majority of genetic changes
introduced during replication would be at the level of genomic RNA
synthesis and, thus, the genetic population within a stock of VEEV
would be more heterogeneous than reported here. Heterogeneity in
the sequence of VEEV was not observed in these studies because the
method used for sequencing only reports the most abundant genetic
information within a population. The application of next generation
sequencing technologies and bioinformatics tools to these questions
would provide a great deal more data on the genetic population
within a viral sample and, for VEEV, may aid in the identiﬁcation of
genetic signatures that would be associated with a given culture
method.
Materials and methods
Cells and viruses
Vero, and C6/36 cells were cultured in Dulbecco's modiﬁed
minimal essential media (DMEM) supplemented with 10% fetal
bovine serum, nonessential amino acids, L-glutamine and Penicillin–
Streptomycin–Neomycin (PSN) antibiotic mixture. Vero cells were
maintained at 37 °C plus 5% CO2. C6/36 cells were kept at 28 °C with
5% CO2.
The VEEV Trinidad Donkey strain was obtained from Dr. Michael
Parker at the USAMRIID in Frederick, MD; and the JEV Nakayama
strain was obtained from Dr. Barbara Johnson at the CDC, Division of
Vector-borne Infectious Diseases in Fort Collins, CO. Parental stocks of
each virus were generated by infecting Vero cells in 175 cm2 ﬂasks
and incubating at 37 °C and 5% CO2 until approximately 80%
cytopathic effect (CPE) was observed. Virus was collected in the
culture supernatant, ﬁltered using a 0.2 μm ﬁlter, aliquoted to 1.5 ml
screw top cryovials and stored at−80 °C. The nucleic acid sequence of
the complete viral genome was determined for each viral stock, along
with viral titer after thawing from−80 °C storage as described below.
Virus stocks were determined to be free of mycoplasma via
polymerase chain reaction using a commercially available kit (Takara
Bio Inc., Madison, WI).
Plaque assays were performed on Vero cells in six well plates by
incubating cellswith0.2 mlof 10-fold serial dilutionsof virus at 37 °C for
1 h. Monolayers were overlaid with 3 ml of Eagle's minimal essential
medium (EMEM) containing 2% FBS, PSN, nonessential amino acids, L-
glutamine, and 1% agarose. VEEV titrations were incubated for
approximately 24 h before addition of 2 ml of secondary overlay
(EMEM contained neutral red at 0.015%). JEV titrations received the
secondary overlay at approximately 72 h post infection. Plaques were
counted on sequential days up to 3 days after addition of the secondary
overlay.
Mice
For newborn CD-1 mice, pregnant dams were ordered from
Charles River Laboratories (Portage, MI) at 13 days gestation and
housed individually in conventional animal facilities until delivery.
For weanling CD-1 mice, 2 week old litters were purchased from
Charles River Laboratories and housed with their dams for one weekin conventional animal facilities before being separated into micro-
isolator cages and transferred to the animal biosafety level 3 (BSL-3)
facility. Food and water were provided ad libitum to all mice. This
research was conducted in compliance with the Animal Welfare Act
and other federal statutes and regulations relating to animals and
experiments involving animals and in adherence to principles stated
in the Guide for the Care and Use of Laboratory Animals (Committee
on Care and Use of Laboratory Animals of the Institute of Laboratory
Animal Resources, National Research Council, NIH Publication No. 86-
23, Revised 1996, NRC Publication, 1996 edition). All procedures were
reviewed and approved by the Institutional Animal Care and Use
Committee at Midwest Research Institute and the Army Animal Care
and Use Review Ofﬁce prior to the initiation of work. All work was
performed in facilities certiﬁed by the Association for Assessment and
Accreditation of Laboratory Animal Care, International.Tissue culture passage
Vero or C6/36 cells in 25 cm2 ﬂasks were infected with VEEV or JEV
at an MOI of 0.1 in 2 ml of media. After 1 h the virus was removed, the
cells were washed 2 times with 3 ml of PBS, and 8 ml of media was
added back to the ﬂasks. C6/36 cells were incubated at 28 °C with 5%
CO2 for 48 (VEEV) or 72 (JEV)h when peak titers were expected to be
achieved in preliminary growth curve studies (data not shown). Vero
cells were incubated at 28 °C with 5% CO2 for 24 (VEEV) or 72 (JEV)h.
The virus was collected from the culture supernatant, ﬁltered through
a 0.2 μm ﬁlter and aliquoted to cryovials for storage at −80 °C. Viral
titers for all frozen stocks were determined by plaque assay on Vero
cells following a single thaw on ice. All passes were performed by
infecting the appropriate cells in culture at an MOI of 0.1 using virus
of known titer that was thawed only once. After 22 passes, Vero cells
infected with JEV were incubated for 48 h before the culture
supernatant was collected due to changes in the accumulation of
viral titers. The ﬁnal pass (pass 40) was performed in 75 cm2 ﬂasks
containing 20 ml of media. For vaccine strains of VEEV (TC-83) and
JEV (SA-14-14-2) more than 80 to 100 passes, respectively, were
required to select for an attenuated virus phenotype (Kinney et al.,
1993; Yu, 2010); however, signiﬁcant changes were observed in as
few as 6 passes in preliminary studies conducted in our labs.We chose
40 passes for this study as a preliminary endpoint that could be
extended depending on the results.Mouse brain passage
Groups of 10 newborn CD-1 mice were inoculated ic with 1×103
pfu of VEEV or JEV in 0.020 ml. Pups were maintained with their dams
for a period of approximately 24 (VEEV) to 48 (JEV)h post-inoculation
before the brains were collected and pooled. The incubation times
correspond to when peak virus titers were expected and were
determined in preliminary time course experiments (data not
shown). Viral stocks were prepared by transferring the pooled brains
to a tissue homogenizer and adding sufﬁcient volume of PBS to
achieve a ﬁnal concentration of 10% (weight/volume). Following
homogenization, the stocks were ﬁltered through a 0.22 μm ﬁlter,
aliquoted to cryovials and stored at −80 °C. Viral titers were
determined for each frozen stock via plaque assay on Vero cells
following a single thaw. Subsequent passes were performed by
inoculating new groups of newborn CD-1 mice as described above
with VEEV MB or JEV MB stocks that had been thawed one time. The
ﬁnal pass was performed using 25 newborn pups. For SINV, between
15 and 22 passes were required to select for a neurovirulent and
neuroinvasive phenotype (Lustig et al., 1992); therefore, 20 passes
were used in these studies as a preliminary endpoint that would
minimize the overall number of mice that would be required.
Table 6
Primer sets for ampliﬁcation of the JEV genome.
Fragment Primer ID Sequence (5′–3′)
1 JEV_00420F GAAGGCTCAATCATGTGGCTCG
JEV_01871R GCCTTTCAGAGCCAGTTTGTCC
2 JEV_01712F GCACGCCACAAAACAGTCC
JEV_03418R CGACAGCACCAGTCAGTGATC
3 JEV_03232F GCAAGCACAATCGGAGGGAAG
JEV_04969R CCGAAGGGAGTCCGAAACAC
4 JEV_04744F TCCACACACTATGGCACACAAC
JEV_06284R GGTGTACTGAATGCCATTGGACG
5 JEV_06173F CGAATACCGTCTCAGAGGTGAAG
JEV_07951R GCTGCGTAGTAGCTCCATCC
6 JEV_07760F GAGAGAGGCCATAATCGAGGTGG
JEV_09441R CTTCTGCTGCAGGTCTCATGAC
7 JEV_09185F GAATTCAGGAGGTGGAGTGGAAGG
JEV_10631R TTTGTGGCCTGACGTTGGTC
5′ RACE 1 JEV_RACE_00740R CTTGGAATGCCTGGTCCGCGTGCACCGTCC
5′ RACE 2 JEV_RACE_00601R SNP1 CCGACGTCGATTGCCCGGACCCAACATCTG
3′ RACE JEV_RACE_10228F SNP1 GGTGTGGCAGCCTTATCGGAACGCGATCC
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Groups of 3, eight day old SPF chicken eggs were inoculated with
5×103 pfu of VEEV or JEV at the yolk sack and incubated for a period of
24 (VEEV) to 48 h (JEV) at 39 °C. The incubation times and the
concentration of virus in speciﬁc egg tissues andﬂuidswere determined
in preliminary time course studies (data not shown). Infected eggswere
kept at 4 °C for a minimum of 4 h before the embryo's were collected,
pooled and homogenized to a ﬁnal concentration of 10% (weight/
volume) in PBS. Stocks of virus were prepared by ﬁltering, aliquoting to
cryovials, and storing at −80 °C. A 0.45 μm ﬁlter was used for these
stocks because the 0.22 μm ﬁlter became clogged by the homogenized
tissues and minimized the volume recovered following harvest. Virus
titers from stocks that were thawed one time were determined by
plaque assay on Vero cells. Subsequent passes were performed as
described above using virus stocks that had been thawed one time. A
total of 6 eggs were used for the ﬁnal pass (pass 20). The endpoint for
egg passage studies was chosen to correspond with the mouse brain
passage study andminimize the number of eggs thatwould be required.
Sequencing
For genomic sequencing, viral RNA was extracted from stocks
using the QIAamp viral RNA minikit (Qiagen) according to the
manufacturer's protocol. RNA was eluted in 50 μl of RNase free H20
and 10% was tested in an in vitro assay for sterility before removing
from the lab.
A fraction of the extractedRNAwasA-tailed usingPoly-A Polymerase
according to manufacturer protocol (Ambion). Adding additional A
nucleotides to the VEEV RNA signiﬁcantly improved the recovery of
cDNA. Full-length genomic cDNAwere then generated using theMMLV
Reverse Transcriptase 1st-Strand cDNA Synthesis Kit (Epicentre)
according to manufacturer protocol. Amplicons corresponding to over-
lapping segments of the viral genomes were ampliﬁed from the cDNAs
using virus speciﬁc primer sets (Tables 5 and 6) according to the
following thermal protocol: 95.0 for 3 min, 35 cycles of 95.0 for 30 s, 64.0
for 30 s, 72.0 for 2 min, followed by a 2-min extension at 72.0.
RACE-ready cDNA was generated using a polyA (3′ end) or speciﬁc
(5′RACE1) primer according tomanufacturer protocol for 3′ (Clontech,
Mountain View, CA) and 5′ (Invitrogen) 1st strand synthesis. 5′ cDNA
was then terminal deoxynucleotidyl transferase tailed prior to
ampliﬁcation according to manufacturer's protocol. RACE-prepared
cDNA was ampliﬁed using virus speciﬁc primers (Tables 5 and 6) for
both the 3′ (3′RACE) and 5′ (5′RACE2) ends according to the following
thermal protocol: 94.0 for 2 min, 40 cycles of 94.0 for 30 s, 68.0 for 30 s,
72.0 for 1 min followed by a 2-min extension.Table 5
Primer sets for ampliﬁcation of the VEEV genome.
Fragment Primer ID Sequence (5′–3′)
1 VEEV_00509F GGTTGACGGACCGACAAGTCTC
VEEV_02145R AGGCGAATTCATGGAAGGGAGG
2 VEEV_01978F GAGGAGCGCTGAACACTGATG
VEEV_03637R AGCCGAGCTCTGAAGGTAGC
3 VEEV_03467F GCCTCATGCTTTAGTCCTCCACC
VEEV_05082R CCTCTGTGGATTGGTTCTCTGC
4 VEEV_04946F GCAGAAGATCCAATGCTCCCAG
VEEV_06642R CAGCCTGGATCACCTGTACC
5 VEEV_06533F GCAGGACATACCAATGGACAGG
VEEV_08180R CTGCTCCATGATGCCAGCTG
6 VEEV_08018F GTGGAAGGCAAGATCGACAACG
VEEV_09665R TGGTGGACATAGGGTATCTGTGG
7 VEEV_09473F CCTCACTACACGCACGAGCTC
VEEV_10874R CTGACACCCTGGTGAACAAGG
5′ RACE 1 VEEV_RACE_00831R CAGACGGCAGGTGCCAGCTCCTCAGTAAGTCCCTC
5′ RACE 2 VEEV_RACE_00732R TTCTAAGAATGGACATCCCTCTACGTGACCGCTCC
3′ RACE VEEV_RACE_10660F GCTGCAGAGACCCAAAGCAGGAGCGATCCACGTGPrimers were removed using the QIAquick PCR Puriﬁcation Kit
and samples were eluted in 50 μl of molecular grade water. Each
sample was sequenced in both directions using BigDye Terminator
v3.1 (Applied Biosystems, Carlsbad, CA) and analyzed on an ABI 3130
capillary sequencer. Sequences were manually trimmed and evaluated
for quality. Sequence alignments were generated using Lasergene
software (DNASTAR).
Virulence assay
Groups of ten weanling CD-1mice were challenged with 1×104 pfu
of VEEV or JEV virus stocks by the IN or SC routes. IN doses were
administered in 0.020 ml total volume using a pipette to directly apply
0.010 ml inoculums to each nostril of an animal anesthetized with
isoﬂuorane. Administration of the dosewas veriﬁed by visual inspection
of the dose site and anesthetized animals were allowed to recover
completely before being returned to their cages. SC inoculations were
performed using a 25 gauge needle to administer 0.200 ml inoculums to
a fold of skin at the back of the neck. Following return to their cages and
racks, micewere observed for a period of up to 14 days for clinical signs
of disease or death. Moribund animals were euthanized, as there is no
evidence for recovery fromclinical diseasewithEEEVor JEV, and theday
of euthanasia was recorded as the day of death.
The percent mortality and 95% conﬁdence bounds were calculated
for each of the viruses by each of the routes. The percent mortality
represents the total number of mice that died as a result of virus
challenge in comparison to the total number of animals that were
challenged. The Fisher's Exact Test was used to compare the percent
mortality for eachvirus to theparent virus in order to identify signiﬁcant
differences. When comparing the virulence of different virus stocks,
particularly when comparing a single dose level, the rate at which
animals succumb to infection is also important and can be determined
bycalculating the survival probabilitieswhich focus on the time todeath
as well as the likelihood of death. In this case, Kaplan–Meier Survival
Curves are used to assess thepercent ofmice that survive challenge over
time for each virus and route. To determine if the survival curves are
equivalent between each virus and the parent the Log-rank test is used.
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